Position in HLN
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$41,813,467
-$1,793,856 QoQ
Shares Held
4,481,615
+2.9% QoQ
Ownership
0.102%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#22
of 639 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Bank Julius Baer & Co. Ltd, Zurich holds $50,041,551 across 9 Drug Manufacturers - Specialty & Generic names. HLN ranks #1 (83.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
This page
|
4,481,615 | $41,813,467 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
23,780 | $4,007,881 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
6,050 | $3,278,071 | |
| 4 | ZTS |
Zoetis Inc.
|
10,367 | $744,972 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
3,236 | $109,635 | |
| 6 | RDY |
Dr Reddys Laboratories Ltd
|
5,000 | $72,450 | |
| 7 | OGI |
Organigram Global Inc.
|
9,838 | $10,034 | |
| 8 | TLRY |
Tilray Brands, Inc.
|
977 | $4,386 |
All Filings in HLN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $41,813,467 | 4,481,615 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $43,607,323 | 4,356,376 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $45,061,877 | 4,457,159 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $38,603,552 | 4,303,629 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $44,498,665 | 4,291,096 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $42,927,369 | 4,171,756 | Shares | Sole | 2025-09-17 | |
| 2024-12-31 | $35,926,342 | 3,765,864 | Shares | Sole | 2025-02-07 | |
| No filing history on record for this holder in this stock. | ||||||